Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University, head, Curie-Montsouris Thorax Institute, discusses the progression-free survival (PFS) data with durvalumab (Imfinzi) observed in a real-world analysis of the phase 3 PACIFIC trial (NCT02125461) in patients with stage III non–small cell lung cancer (NSCLC).
The real-world analysis, or the PACIFIC-R trial (NCT03798535), found that the median PFS in patients treated with durvalumab was 21.7 months, according to Girard. This result is higher than the benefit reported in the PACIFIC study, which is rare, as patients selected for clinical trials often have a better performance status than those in a real-world setting, Girard explains.
Because the analysis is retrospective, there may be bias regarding the time intervals between imaging assessments, Girard notes. However, the data are important because they confirm the efficacy of durvalumab, which is a standard-of-care treatment for this patient population, Girard concludes.